DDInter1035 DDInter899
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Lenalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
Lenalidomide {u} (Compound) upregulates {v} (Gene) RRP8
Lenalidomide {u} (Compound) downregulates {v} (Gene) GDF15
Lenalidomide {u} (Compound) causes {v} (Side Effect) Cholecystitis
Lenalidomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Lenalidomide (Compound) resembles Thalidomide (Compound)
Lenalidomide (Compound) resembles Pomalidomide (Compound)
Lenalidomide (Compound) treats hematologic cancer (Disease)
Lenalidomide (Compound) binds PTGS2 (Gene)
Lenalidomide (Compound) upregulates RRP8 (Gene)
Lenalidomide (Compound) downregulates GDF15 (Gene)
Lenalidomide (Compound) causes Cholecystitis (Side Effect)
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol